Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion

Circulation Research

Volumn 113, Issue 2, 2013, Pages 167-175

  Siebel, Andrew L ^a   Natoli, Alaina K ^a   Yap, Felicia Y T ^a   Carey, Andrew L ^a   Reddy Luthmoodoo, Medini ^a   Sviridov, Dmitri ^a   Weber, Chek Ing Kiu ^b   Meneses Lorente, Georgina ^b   Maugeais, Cyrille ^b   Forbes, Josephine M ^a   Kingwell, Bronwyn A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

cholesterol homeostasis; high density lipoprotein cholesterol; insulin secretion; lipoproteins; oxidized low density lipoprotein; type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENZYME INHIBITION; EX VIVO STUDY; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

CHOLESTEROL HOMEOSTASIS; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN SECRETION; LIPOPROTEINS; OXIDIZED LOW-DENSITY LIPOPROTEIN; TYPE 2 DIABETES MELLITUS;

ANIMALS; CELL LINE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FASTING; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; RATS; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84880565426     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.113.300689     Document Type: Article

References (48)

1. Drew BG, Duffy SJ, Formosa MF, et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009;119:2103-2111.
2. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann C, Waeber G. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia. 2007;50:1304-1314.
3. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642-1648.
4. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem. 2003;278:18368-18375.
5. Rütti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY, von Eckardstein A. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 2009;150:4521-4530.
6. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, Cui G, He J, Liu W, Chen Y. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia. 2007;50:1960-1968.
7. Brewer HB Jr. Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab. 2011;96:1246-1257.
8. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-2415.
9. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777-783.
10. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008;149:2208-2218.
11. Zhang X, Bao Y, Ke L, Yu Y. Elevated circulating free fatty acids levels causing pancreatic islet cell dysfunction through oxidative stress. J Endocrinol Invest. 2010;33:388-394.
12. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-3887.
13. Xiao C, Giacca A, Lewis GF. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipidinduced insulin resistance and beta-cell dysfunction in humans. Diabetes. 2011;60:918-924.
14. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340-347.
15. Kruit JK, Kremer PH, Dai L, Tang R, Ruddle P, de Haan W, Brunham LR, Verchere CB, Hayden MR. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia. 2010;53:1110-1119.
16. Ishikawa M, Iwasaki Y, Yatoh S, Kato T, Kumadaki S, Inoue N, Yamamoto T, Matsuzaka T, Nakagawa Y, Yahagi N, Kobayashi K, Takahashi A, Yamada N, Shimano H. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J Lipid Res. 2008;49:2524-2534.
17. Fryirs M, Barter PJ, Rye KA. Cholesterol metabolism and pancreatic betacell function. Curr Opin Lipidol. 2009;20:159-164.
18. Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol. 2010;21:178-185.
19. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012;8:237-245.
20. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124:555-562.
21. Zhang Q, Wan R, Guo R, Jin L, Liu Y, Li S. Long-term high density lipoprotein infusion ameliorates metabolic phenotypes of diabetic db/db mice. Diabetes Metab Res Rev. 2013;29:130-138.
22. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197-2202.
23. Shinkai H. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manag. 2012;8:323-331.
24. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
25. Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099.
26. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099-2109.
27. Puhl H, Waeg G, Esterbauer H. Methods to determine oxidation of lowdensity lipoproteins. Methods Enzymol. 1994;233:425-441.
28. Yancey PG, Jerome WG. Lysosomal cholesterol derived from mildly oxidized low density lipoprotein is resistant to efflux. J Lipid Res. 2001;42:317-327.
29. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 1996;126:65-75.
30. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, Yamamura K. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology. 1990;127:126-132.
31. Coughlan MT, Yap FY, Tong DC, et al. Advanced glycation end products are direct modulators of {beta}-cell function. Diabetes. 2011;60:2523-2532.
32. Favre D, Niederhauser G, Fahmi D, Plaisance V, Brajkovic S, Beeler N, Allagnat F, Haefliger JA, Regazzi R, Waeber G, Abderrahmani A. Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets. Diabetologia. 2011;54:2337-2346.
33. Lu X, Liu J, Cao X, Hou X, Wang X, Zhao C, Wang Y, Li Y, Seo H, Gao B. Native low density lipoprotein induces pancreatic β cell apoptosis through generating excess reactive oxygen species. Lipids Health Dis. 2011;10:123.
34. Lapointe J, Truong TQ, Falstrault L, Brissette L. Differential abilities of mouse liver parenchymal and nonparenchymal cells in HDL and LDL (native and oxidized) association and cholesterol efflux. Biochem Cell Biol. 2006;84:250-256.
35. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 2009;120:2095-2104.
36. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-219.
37. Halter JB, Ward WK, Porte D Jr, Best JD, Pfeifer MA. Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver. Am J Med. 1985;79:6-12.
38. Monnier L, Colette C, Leiter L, Ceriello A, Hanefeld M, Owens D, Tajima N, Tuomiletho J, Davidson J; PGR Group. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2007;30:185-186; author reply 187.
39. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349-1354.
40. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ, Hayden MR, Stroes ES. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care. 2010;33:869-874.
41. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic betacell dysfunction. Diabetes. 2007;56:2328-2338.
42. Vikman J, Jimenez-Feltström J, Nyman P, Thelin J, Eliasson L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J. 2009;23:58-67.
43. Kruit JK, Wijesekara N, Fox JE, et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 2011;60:3186-3196.
44. Koseki M, Matsuyama A, Nakatani K, et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb. 2009;16:292-296.
45. Kruit JK, Wijesekara N, Westwell-Roper C, Vanmierlo T, de Haan W, Bhattacharjee A, Tang R, Wellington CL, LütJohann D, Johnson JD, Brunham LR, Verchere CB, Hayden MR. Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired β-cell function. Diabetes. 2012;61:659-664.
46. Xu X, London E. The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation. Biochemistry. 2000;39:843-849.
47. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331-340.
48. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164.